Effect of a Natural Health Product on Urinary Estrogen Metabolites
A Clinical Trial to Assess the Efficacy of a Supplemental Formula Targeting Breast Health in Beneficially Altering Urinary Estrogen Metabolites Levels in Both Pre- and Post-menopausal Women
研究概览
详细说明
The active botanical constituents in femMED Breast Health Formula contain lignans, compounds with anti-estrogenic activity, that have been shown to exert an estrogenic effect during the follicular phase [i.e. when estrogen is low] and an antiestrogenic effect in the luteal phase of a female menstrual cycle. These are plant-derived chemicals that can act as weak mimics of estrogen in the body. Overall these compounds have been found to be helpful in stabilizing the natural cyclical fluctuation of estrogen levels.
The trial will be a double-blind, placebo-controlled parallel study in which 100 subjects will be recruited to one of two arms of the study: one arm will consist of pre-menopausal women; another will consist of post-menopausal women. Each arm of the study will be carried out concurrently and in one phase, with no washout period. The placebo assignment will be randomized within each arm of the study.
Subjects in each arm of the study will follow the same protocol. Urine and blood samples will be collected from each group at both the first and last visit, and subjects will receive a month's supply of treatment or placebo at the first visit, which they will consume on a daily basis until their second lab visit 28 days later. Urine samples will be analyzed for the following estrogen metabolites: 2-OH-estrone and 16-α OH-estrone. Blood samples would be collected and assessed for levels of enterolactone. Pre and post-supplementation results will be assesses for any differences by statistical comparison.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Ontario
-
Guelph、Ontario、加拿大、N1G0B4
- Nutrasource Diagnostics Inc
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- 18 years of age or older
- Healthy
- Willing to collect urine samples and to have blood drawn
- Post-menopausal and have not taken hormone replacement therapy (HRT) in the past year (48 subjects)
- Pre-menopausal (48 subjects)
Exclusion Criteria:
- Diagnosed with any major illness(e.g. cancer)
- Diabetes, thyroid disease, atypical hyperplasia, fibrocystic breast disease, family history of ovarian cancer, a history of "migraines with aura"
- Women taking blood thinner or thyroid medication (including warfarin)
- Known allergy to any of the any of the study ingredients
- Pregnancy or lactation
- Regular consumption in the previous 3 months of any other natural health products (NHPs) or pharmaceutical containing ingredients with a similar effect on estrogen metabolism as those included in the femMED Breast Health treatment
- Family history of breast cancer risk
- Post-menopausal women on HRT
- Pre-menopausal women taking hormonal contraceptives (oral contraceptives, the patch etc.)
- All other forms of estrogen, progesterone and/or androgens (i.e. testosterone therapy)
学习计划
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pre-Menopausal
|
Two capsules daily, with meals.
FemMED Breast Health Formula containing lignans.
|
|
实验性的:Post-Menopausal
|
Two capsules daily, with meals.
FemMED Breast Health Formula containing lignans.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
2-OH Hydroxy Estrone: 16-alpha-OH Estrone
大体时间:Day 0, Day 28
|
2-OHE:16α-OHE1 (2:16 ratio) - 2:16 ratios less than 2.0 indicate increasing long-term risk for breast, cervical, and other estrogen sensitive cancers. Urine samples will be analyzed for the following estrogen metabolites: 2-OH-estrone and 16-α OH-estrone. |
Day 0, Day 28
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Enterolactone
大体时间:Day 0, Day 28
|
Enterolactone is a lignan formed by the action of intestinal bacteria on lignan precursors found in plants. For the purpose of this study, enterolactone will serve as an indicator of compliance/dietary intake of lignans. Blood samples would be collected and assessed for levels of enterolactone. |
Day 0, Day 28
|
合作者和调查者
调查人员
- 首席研究员:Maggie Laidlaw, P.hD、Nutrasource Pharmaceutical and Nutraceutical Services, Inc.
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- NDI: 136987
- NHPD136987 (其他标识符:Natural Health Products Directorate, Health Canada)
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.